Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 18/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 15/20 | 0.41 |
| ▸ | PDE1A | P54750 | 14/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748877 | 0.88 | PDE1C (0.44) | PDE1CPDE1BPDE1A | |
| SCHEMBL400651 | 0.86 | PDE1C (0.43) | PDE1CPDE1BPDE1A | |
| SCHEMBL594279 | 0.85 | PDE1C (0.38) | PDE1CPDE1BPDE1A | |
| SCHEMBL18099738 | 0.85 | PDE1C (0.46) | PDE1CPDE1BPDE1A | |
| SCHEMBL25378663 | 0.84 | PDE1C (0.39) | PDE1CPDE1BPDE1A | |
| SCHEMBL13962521 | 0.84 | PDE1C (0.47) | PDE1CPDE1BPDE1A | |
| SCHEMBL4313118 | 0.81 | PDE1C (0.40) | PDE1CPDE1BPDE1A | |
| SCHEMBL2327173 | 0.81 | PDE1C (0.50) | PDE1CPDE1BPDE1A | |
| SCHEMBL13962531 | 0.81 | PDE1C (0.37) | PDE1CPDE1BPDE1A | |
| SCHEMBL2321250 | 0.80 | PDE1C (0.36) | PDE1CPDE1BPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4041401-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071919-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | HCK, LYN, BTK | PDE1C 1557/4885PDE1B 868/4885PDE1A 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.